11results about How to "Good tissue penetration" patented technology

The invention belongs to the technical field of medical examination, and particularly relates to preparation and application of a polymerase-labeled secondary antibody. The preparation method comprises the following steps: activating enzyme by divinyl sulfone (DVS), polymerizing with hyperbranched aminated polyethylene glycol to obtain polymer enzyme, activating the polymer enzyme again, and incubating with a second antibody to obtain a polymer-labeled second antibody. According to the method, the main defects of the secondary antibody in the current market are overcome, the enzyme label density on the antibody is improved, and the number of enzyme molecules labeled on the secondary antibody in unit volume is greatly increased; the volume of the polymer enzyme is reduced; the cell penetrability of the enzyme-labeled secondary antibody is improved, and the sensitivity and the stability are higher.

The application discloses a kind of medical titanium alloy material surface antibacterial functionalization processing methods, first by hydrothermal oxidation and high-temperature sintering processing in titanium alloy material surface construction TiO2 Nanometer sheet, then deposit W 18 O 49 Quantum dots are deposited on the TiO2 Nanometer sheet, and TiO2 / W 18 O 49 Heterojunction is constructed on the surface of titanium alloy.TiO2 / W 18 O 49 Heterojunction can efficiently catalyze the production of reactive oxygen species (ROS) under near-infrared light irradiation, achieving antibacterial function. The TiO2 / W 18 O 49 Heterojunction functionalized titanium alloy material surface, the irregular sheet structure of TiO2 Nanometer sheet can greatly increase the contact area of the material surface and the surrounding solution, and the W 18 O 49 Quantum dots have the characteristics of "single-atom-like catalysis", which can improve the ROS yield and further endow the medical titanium alloy surface with strong photodynamic antibacterial performance.

This invention belongs to the field of biodetection technology, specifically relating to a method for preparing and applying a fluorescent probe for screening monoamine oxidase B inhibitors. The method for preparing the fluorescent probe described in this invention is simple, convenient, and low in synthesis cost. The fluorescent probe prepared using this method exhibits good specificity and high sensitivity. The probe has a large fluorescence emission wavelength, which can effectively avoid fluorescence interference from chemical components in traditional Chinese medicine, thereby improving detection sensitivity. It shows promising application prospects in the screening of monoamine oxidase B inhibitors from traditional Chinese medicine.

The present invention discloses a preparation method and biological application of a fluorescent probe with lipid droplet recognition and polarity sensitivity. The fluorescent probe CN obtained by the present invention can efficiently and accurately target lipid droplets. The preparation method adopted by the molecule is simple and the conditions are mild. The maximum emission wavelength of the fluorescent probe is at 724nm, which can realize near-infrared I zone fluorescence imaging, and the maximum Stokes shift can reach about 190nm. The maximum emission wavelength and the maximum excitation wavelength have a large wavelength difference, thereby solving the problem of autofluorescence quenching in the measurement, and the background interference is low and the detection sensitivity is high. In the environment inside the lipid droplet, the fluorescence of the probe CN is significantly enhanced, and it can efficiently and accurately target the lipid droplets, detect changes in the number of lipid droplets and changes in polarity in cells. Imaging experiments at the cell and tissue animal level show that it has good biosafety and good photostability. The probe CN provides a reliable tool for further studying the dynamic changes of lipid droplets and the occurrence and development of Parkinson's disease.

This invention discloses an extracellular vesicle derived from Sophora flavescens, its preparation method, and its application. It belongs to the field of biomedical technology. The extracellular vesicles derived from Sophora flavescens are obtained by isolating extracellular vesicles (SF-EVs) from the roots of Sophora flavescens. These vesicles have a particle size of 100-200 nm and contain proteins, lipids, high abundance of miR6300, and various alkaloids. This invention also provides a method for preparing the extracellular vesicles and further provides their application in the preparation of drugs for treating metabolic-associated steatohepatitis (MASH). In vitro and in vivo experiments have demonstrated that SF-EVs can significantly improve lipid accumulation, inflammatory response, and oxidative stress in MASH, with an overall therapeutic effect superior to an equivalent dose of total alkaloids from Sophora flavescens. Through protein / RNA knockout, transcriptome sequencing, and mechanism verification, miR6300 was found to be a key effector of SF-EVs in its anti-MASH effect, and it exerts a synergistic therapeutic effect by dually targeting CYP2B6 (improving lipid metabolism) and CXCL10 (inhibiting inflammation).

The application discloses a microwave-responsive hydrogel dressing and application thereof in preparation of an anti-diabetic chronic infection wound preparation. The raw material of the hydrogel dressing disclosed by the application comprises: (A) a hydrogel matrix; (B) glucose oxidase; (C) a nano-enzyme composition, wherein the nano-enzyme composition at least comprises a luteolin-manganese dioxide composite; wherein the luteolin-manganese dioxide composite is a solid-phase product obtained by wet blending of luteolin and nano-manganese dioxide. Under microwave irradiation, the heat effect generated by the microwave causes the hydrogel dressing to heat up, the heat-enhanced glucose oxidase consumes glucose to generate hydrogen peroxide, and at the same time, the heat-enhanced luteolin-manganese dioxide composite decomposes the hydrogen peroxide to generate oxygen, thereby simultaneously relieving high glucose and hypoxia, fundamentally breaking the vicious cycle of "high glucose-hypoxia-infection-chronic inflammation" of the diabetic wound, and finally improving the antibacterial effect on the skin wound.

The present invention discloses a near-infrared femtosecond laser simulation-induced vascular embolism system. Rose Bengal reagent is pre-injected into the cerebral cortical blood vessels; the femtosecond laser is stimulated to generate a specific near-infrared 1070nm femtosecond laser and is incident on the two-photon microscope system to focus on the cerebral cortical blood vessel area of ​​interest; repeated spiral rapid scanning stimulation is performed in the area of ​​interest ROI to form a thrombus, and the imaging laser is also processed to generate an imaging beam and focused on the cerebral cortical blood vessels for real-time vascular imaging; the imaging laser generates an imaging beam and is incident on the two-photon microscope system; the stimulating femtosecond laser and the imaging laser are controlled to work according to the scanning imaging sequence. The present invention combines 1070nm near-infrared femtosecond laser stimulation with two-photon microscopic imaging technology to achieve precise and rapid thrombosis of blood vessels of various types, sizes and depths. It is a new and more effective system for the formation of targeted vascular thrombus, which is fast, accurate and has depth selectivity.

The invention specifically discloses a CD16A targeted binding protein as well as a derivative and application thereof, and relates to the technical field of biological medicines. The CD16A targeting binding protein provided by the invention has high affinity to CD16A, the molecular weight of the CD16A targeting binding protein is only about 18kDa and is about one tenth of that of an antibody, and the CD16A targeting binding protein has good tissue penetrability, is simple in production process and high in yield, has good targeting property to NK cells with positive CD16 expression, has an efficient immune activation effect, and can be used for preparing the immunopotentiator. The compound can promote the killing effect of an organism immune system on tumor cells, and can be used for tumor targeted drug delivery or NK cell targeted drug delivery and tumor immune cell therapy. The invention provides a theoretical basis and an experimental basis for developing a new treatment strategy, and has good clinical transformation and clinical application prospects.

The present application relates to the technical field of nanobody, in particular to anti-FcRH5 nanobody and its application. The present application provides a kind of anti-FcRH5 nanobody with high affinity and specificity, which is based on the single domain heavy chain variable region structure of camelid origin, with the advantages of small molecular weight, high stability, strong tissue penetration, easy to be engineered and the like. The nanobody specifically recognizes and binds to the target point highly expressed and stably expressed on the surface of multiple myeloma cells through its complementarity determining region. The nanobody of the present application can be used as a core recognition element to construct a variety of therapeutic or diagnostic tools such as chimeric antigen receptor T cells, bispecific antibodies, antibody drug conjugates or immunodetection probes. The technical scheme can solve the technical problem that there is a lack of high-quality, functionally clear anti-FcRH5 antibody in the prior art. The nanobody of the present application has significant clinical transformation and industrialization advantages, and promotes the treatment of multiple myeloma to multiple target points.

This invention relates to the fields of antibody engineering and tumor diagnosis and treatment technology, specifically to CLDN6 nanobodies that recognize different epitopes and their related applications. To develop more nanobodies that recognize CLDN6, this invention provides two nanobodies capable of recognizing different epitopes of CLDN6, each recognizing a different antigenic epitope of the CLDN6 protein, wherein the different epitopes are spatially independent or partially overlapping. These nanobodies can be used alone or in combination and are suitable for tumor targeted therapy, immunotherapy, in vivo or in vitro diagnostics, and molecular imaging. Compared with existing technologies, the CLDN6 nanobodies provided by this invention have the advantages of small molecular weight, high stability, and strong specificity. Through a multi-epitope recognition strategy, the risk of antigen escape can be significantly reduced, and the targeting binding ability and application flexibility can be improved, making them of significant application value in the diagnosis and treatment of CLDN6-positive tumors.

The present invention belongs to the field of biotechnology, and discloses a single-domain antibody targeting HLA-DRB5 and its application. The amino acid sequence of the single-domain antibody targeting HLA-DRB5 of the present invention is: any sequence shown in SEQ ID NO.3, 5, 7, 9, 11, 13, 15, 17, 19, 21. The single-domain antibody targeting HLA-DRB5 of the present invention has good tissue penetration, high specificity, good water solubility, high stability, and low storage condition requirements. It can be used to diagnose changes in HLA-DRB5 expression and treat related diseases caused by increased HLA-DRB5 expression.